Shingles Vaccine Linked to 24% Drop in Dementia Risk

Getting a shingles vaccine might do more than prevent a painful rash. It could also help protect your brain.

Researchers at Brown University studied the health records of more than 509,000 adults over age 66 who lived in skilled nursing facilities. Those who received at least one dose of Shingrix, the recombinant shingles vaccine, showed a 24% reduction in dementia risk compared to those who skipped the shot.

The findings, published in The Annals of Internal Medicine, tracked participants over four years. This research marks the third or fourth study to reach similar conclusions, building a compelling case for an unexpected benefit of routine vaccination.

Dr. Ajeet Sodhi, a neurologist in Orlando who wasn't involved in the study, calls the pattern "remarkable." He notes that the consistency across multiple studies makes the connection harder to dismiss as coincidence.

Scientists have proposed several explanations for why the vaccine might help protect cognitive function. The shingles virus itself has been linked to stroke and other vascular problems that can lead to dementia, so preventing the illness might prevent these cascading effects.

Recent research published this week strengthens this theory, showing that the shingles vaccine also reduces heart attacks and strokes. These cardiovascular benefits could be key to understanding how the shot protects the brain.

The vaccine isn't classified as a dementia treatment, and researchers stress they've found an association, not definitive proof. But for a vaccine already recommended for preventing the excruciating nerve pain of shingles, the potential brain benefits feel like a bonus.

Why This Inspires

This discovery reminds us that medical progress often happens in unexpected ways. A vaccine designed to prevent a painful rash might also help millions avoid cognitive decline, one of the most feared aspects of aging.

The timing matters too. The CDC already recommends Shingrix for all adults 50 and older, meaning the infrastructure to deliver this potential benefit already exists.

Dr. Sodhi emphasizes that early action makes the biggest difference for brain health. Anyone concerned about memory loss or family history should talk to their doctor sooner rather than later, as treatments work best in the earliest stages.

The study was funded by GSK, which makes Shingrix, though the company had no role in designing, analyzing, or publishing the research. The authors maintained full independence in their findings.

For the millions of older adults already eligible for the shingles vaccine, this research offers one more reason to roll up their sleeves and one more reason to feel hopeful about healthy aging.